- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00028028
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients With Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease After Induction Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To study the progression-free survival in patients who receive a lower or a higher dose of CCI-779, a cytostatic agent following cytoreductive chemotherapy in extensive SCLC.
II. To determine the toxicity of two treatment regimens involving a lower or a higher dose of CCI-779.
SECONDARY OBJECTIVES:
I. To quantify the effects of CCI-779 treatment on p70S6 phosphorylation in peripheral blood mononuclear cells of patients with small cell lung cancer who are treated with CCI-779.
II. To measure the effects on mTOR activation and signaling of plasma from patients treated with CCI-779.
III. To determine the relationship between CCI-779 dose and its pharmacodynamic parameters.
IV. To correlate the inhibition of p70S6 with indices of patient outcome.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to brain metastases (yes vs no), prior induction chemotherapy regimen (platinum and etoposide vs platinum and irinotecan), and response to prior induction chemotherapy (complete or partial response vs stable disease). Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive high-dose CCI-779 as in arm I.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Eastern Cooperative Oncology Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have histologically-confirmed small cell carcinoma of the lung or unequivocally positive cytological evidence (sputum [at least 2] or aspirate biopsy), with extensive disease (disease beyond the hemithorax and adjacent nodes, supraclavicular node involvement or pleural effusion with positive cytology), who have required induction chemotherapy, who have responding or stable disease, and who meet the following criteria:
- Induction chemotherapy including platinum (cisplatin or carboplatin) plus either etoposide (VP-16) or irinotecan (CPT-11)
- A minimum of 3 and a maximum of 6 cycles of induction chemotherapy have been administered
- Recovered from all toxicity related to prior chemotherapy (except alopecia and/or neuropathy)
- No less than 4 and no more than 8 weeks have elapsed between the last treatment of induction chemotherapy and randomization
- No more than 32 weeks have elapsed between the first dose of induction chemotherapy and date of randomization
- The patient has responding or stable disease using RECIST criteria since the initiation of systemic chemotherapy (i.e., patients who have exhibited disease progression are NOT ELIGIBLE)
- Patients must be disease-free for >= 5 years if they have had a prior second malignancy other than treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
- Baseline measurements/evaluations of disease must be obtained =< 4 weeks prior to randomization
- WBC >= 4000/mm³ or
- ANC >= 1500/mm³
- Platelet count >= 100,000/mm³
- Total bilirubin =< 1.5 mg/dl
- Creatinine =< 1.5 mg/dl
- Patient's cholesterol level must be < 350mg/dl; (note; if non-fasting levels are high repeat in a fasting state)
- Patient's triglycerides must be < 400mg/dl; (note; if non-fasting levels are high repeat in a fasting state)
- ECOG performance status 0, 1, or 2
- Prior radiation to any symptomatic site is permitted so long as the site(s) of measurable disease are NOT irradiated, and radiation is completed at least 4 weeks before randomization
- Patients must not have had prior treatment with biological response modifiers
- Patients with brain metastases are eligible provided they have received treatment, are asymptomatic and are no longer taking corticosteroids; patients who develop brain metastases after completion of induction chemotherapy are ineligible
- Patients must not be on anticonvulsant therapy
- Patients must not have limited disease
- Patients must not become pregnant and must practice adequate contraception; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and continue approximately 12 weeks after the study is completed; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; female patients who are breastfeeding are also excluded from this study
- Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to CCI-779, or to any of the components of the CCI-779 formulation; patients must also not be allergic to or for medical reasons are unable to receive antihistamines
- Patients must not be immunocompromised, have an active infection or serious intercurrent infection, or have received known immunosuppressive therapies within 3 weeks randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive low-dose CCI-779 IV over 30 minutes once weekly.
Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given IV
Other Names:
|
Experimental: Arm II
Patients receive high-dose CCI-779 as in arm I.
|
Correlative studies
Correlative studies
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Time to death or relapse, assessed up to 6 years
|
A log-rank test will compare the PFS curves of both arms.
|
Time to death or relapse, assessed up to 6 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity rate graded according to NCI CTC version 2.0
Time Frame: Up to 6 years
|
The difference in the true toxicity rates of the two arms will be detected using Fisher's exact test.
|
Up to 6 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kishan Pandya, Eastern Cooperative Oncology Group
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- NCI-2012-03146
- U10CA021115 (U.S. NIH Grant/Contract)
- E1500
- CDR0000069118 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extensive Stage Small Cell Lung Cancer
-
Zhejiang Cancer HospitalRecruitingExtensive Stage Lung Small Cell CancerChina
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Shanghai Chest HospitalRecruitingSmall Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer, Combined TypeChina
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
European Organisation for Research and Treatment...UNICANCERRecruitingExtensive-stage Small-cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited Kingdom, Belgium, Switzerland, Italy, France, Germany, Poland, Spain, Austria
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedSmall Cell Lung Cancer | Small Cell Lung Cancer Limited Stage | Small Cell Lung Cancer Extensive StageFrance
-
University of WashingtonAstraZenecaWithdrawnStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung CancerUnited States
-
Washington University School of MedicineMerck Sharp & Dohme LLCWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States